NeuroNOS

@Neuro_NOS

A Biotech company solely focused on brain disorders, pioneering a unique platform to develop a new class of therapies for Autism, Alzheimer's, and Glioblastoma.

Boston, MA

neuro-nos.com

Replies Reposts Media

NeuroNOS
@Neuro_NOS
Sep 9, 2025
Proud to share: the FDA has granted Orphan Drug Designation to BA-101 for Glioblastoma (GBM) — the most common malignant brain cancer in adults. This is our 2nd ODD in 2025, advancing our mission to deliver targeted nitric-oxide–modulating therapies. stocks.apple.com/AiEjITBE8QwCR7…
NeuroNOS
@Neuro_NOS
Aug 26, 2025
Glioblastoma (GBM) is the most aggressive brain cancer, with survival often measured in months despite current treatments. At NeuroNOS, we’re developing a novel nNOS inhibitor to rebalance nitric oxide signaling that fuels tumor growth. #NeuroNOS #Glioblastoma #braincancercure
NeuroNOS
@Neuro_NOS
Aug 21, 2025
In a landmark Redox Biology review, our CSO Prof. @haitham_amal (@NeuroNOS) with Tripathi & Kartawy highlighted how NO dysregulation drives brain disorders. We’re building on these insights with a selective nNOS inhibitor for ASD. @Elsevier #NeuroNOS #AutismResearch #NitricOxide
NeuroNOS
@Neuro_NOS
Aug 18, 2025
We’re proud our CSO, Prof. @haitham_amal, will speak at #Synchrony2025 on Aug 22! His nitric oxide work shapes our mission at @Neuro_NOS. Thanks to the BRAIN foundation, @BostonChildrens, @HebrewU, and the Rosamund Stone Zander Center for advancing this dialogue #AutismResearch
NeuroNOS
@Neuro_NOS
Aug 14, 2025
#ThrowbackThursday: Prof. @haitham_amal’s lab (our CSO) found disrupted autophagy proteins in two ASD models, driven by NO imbalance. Blocking nNOS restored normal function—reinforcing NeuroNOS’s approach to rebalance NO & tackle core ASD biology. #AutismResearch #NeuroNOS